

AA 1. (Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound selected from the group consisting of substituted benzimidazoles and pancreatic enzyme supplements, said method comprising:

a. providing an active pharmaceutical compound;

b. providing a basic salt as one of a powder, a suspension and a solution having a pH greater than 7;

c. combining said active pharmaceutical compound in a form as one of a tablet, a capsule, and a powder with said basic salt as one of the powder, the solution and the suspension to convert said acid-labile pharmaceutical compound into a non-enteric coated tablet, capsule or liquid formulation; and

d. delivering the non-enteric coated liquid formulation of said acid-labile pharmaceutical compound to patients who are unable to swallow intact capsules or tablets orally by an artificial feeding

A 1
cont

tube inserted in the patients'
gastrointestinal tract.

A 2

3. (Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound as claimed in Claim 1, wherein said basic salt is one of a Type IA and Type II metal salt.

4. (Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound as claimed in Claim 3, wherein said metal salt is one of sodium, potassium, magnesium, calcium and aluminum.

A2
Cost

5. (Amended) A method for the formulation and delivery of an acid-labile pharmaceutical compound as claimed in Claim 1, wherein said compound in said formulation includes a therapeutic dose of said active pharmaceutical compound.

A 3

7. (Amended) An acid-labile pharmaceutical compound having at least substituted benzimidazoles and pancreatic enzyme supplements, said acid-labile pharmaceutical compound comprising:

- a. an active pharmaceutical compound;
- b. a basic salt, which basic salt is at least one of a powder, a solution and a suspension;
- c. said one of said powder, said solution and said suspension having a pH greater than 7.0;
- d. said active pharmaceutical compound and said basic salt combined as at least one of a form of a tablet, capsule, and powder;

A 3
Card

e. said at least one of a form of a tablet, capsule and powder provided to said one of said solution and said suspension to convert said acid-labile pharmaceutical compound into a non-enteric coated tablet, capsule, or liquid formulation which is operable to provide at least one of neutralization of gastric acid and temporary stimulation of gastric acid secretion; and

the non-enteric coated liquid formulation of said acid-labile pharmaceutical compound being delivered to patients who are unable to swallow intact capsules or tablets orally by an artificial feeding tube inserted in the patients' gastrointestinal tract.

A 4

13. (Amended) An acid-labile pharmaceutical compound as claimed in Claim 7, wherein said artificial feeding tube [being] is at least one of nasogastric tube, nasoduodenal tube, nasojejunal tube, orogastric tube, oroduodenal tube, orojejunal tube, gastrostomy tube and jejunostomy tube.
